Specialty Pharmacy

Christopher W. Kennedy, MSM, Chief Operating Officer, Heritage Biologics, discusses how data can translate to improvements in patient care.

Top news of the day from across the health care landscape.

Artificial intelligence could take over medication dispensing in the next 50 years.

Kansas sought to cap Medicaid benefits at 3 years, a proposal that health care providers, hospitals, and advocates called cruel.

Pharmacy information systems streamline and standardize the data entry process, reduce errors, and save countless hours of labor.

Top news of the day from across the health care landscape.

The combination therapy dabrafenib plus trametinib approved for the treatment of BRAF V600 mutation-positive anaplastic thyroid cancer that cannot be removed by surgery or is metastatic.

Lonafarnib, a farnesyltransferase inhibitor, extended survival in patients with Hutchinson-Gilford progeria syndrome, or progeria.

PaxVax, an independent specialty vaccine company, is developing the prophylaxis.

Tisagenlecleucel (Kymriah, Novartis) is now approved for the treatment of diffuse large B-cell (DLBCL) lymphoma, as well as high grade B-cell lymphoma and DLBCL arising from follicular lymphoma.

Top news of the day from across the health care landscape.

Top news of the week from Specialty Pharmacy Times.

Trametinib plus dabrafenib is the first oral targeted adjuvant combination therapy to demonstrate significant clinical benefit in patients with a BRAF V600 mutation, following complete surgical resection.

The study found a calculable personal genetic risk score that was applicable to approximately 60,000 patients.

Although current guidelines recommend that HIV primary care intervals do not exceed 6 months, gaps in care up to 9 months do not worsen viral load for patients.

This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings, and more. Our Week in Review is a can't miss for the busy pharmacy professional.

Top news of the day from across the health care landscape.

BLU-667 is being investigated for the treatment of cancers caused by an alteration in the receptor tyrosine kinase.

Half of all HAE drug expenses were billed through the pharmacy benefit and half through the medical benefit.

HIV targets and disables a pathway involved in blocking viral activity and clearing infection.

At the 2018 National Community Oncology Dispensing Association (NCODA) Spring Summit, Ali McBride, PharmD, MS, BCPS, BCOP, explains what strategies can help ensure patients are adherent to oral chemotherapy regimens.

Poor study design and reporting in animal research compromises the ethical review of proposed human drug trials.

A synthetic bridged nucleic acid was found to greatly improve the accuracy of gene-editing technology, which could potentially lead to new therapies for genetic diseases.

People living with HIV are at elevated risk for hyponatremia, the most common electrolyte disorder seen in hospitals.

The new method indexes thousands of cells simultaneously and could potentially improve understanding of various diseases at a molecular level.

The findings suggest that a patient’s diet may impact their ability to combat head and neck cancer.

At the 2018 National Community Oncology Dispensing Association (NCODA) Spring Summit, Ray Bailey, BPharm, RPh, Pharmacy Director at Florida Cancer Speciality, discusses interventions aimed at reducing the waste and cost of expensive oral chemotherapy treatments.

In the largest study of its kind, breast cancer survivors were not found to have a greater mortality risk due to heart disease than the general population.

Unintentional weight loss may allow physicians to detect cancer sooner.

Burosumab (Crysvita, Ultragenyx) is the first treatment approved for x-linked hypophosphatemia in adults and children ages 1 and older.